Research analysts at Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for Tri Pointe Homes in a research ...

Dan Ives, Wedbush Securities global head of technology research and senior equity analyst, joins 'Squawk Box' to discuss ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...

Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to break down ...

Dan Ives, Managing Director and Senior Equity Analyst at Wedbush Securities, shares his expert insights on the future of AI, ...

Wedbush made a splash on Tuesday with the announcement that it was entering the ever-growing ETF market. Read more here.

However, Wedbush Securities sees the reaction as overblown. Analyst Dan Ives and his team argue that instead of hurting Palantir, the proposed cuts could actually work in its favor. With the ...

Wedbush analyst Robert Driscoll last night initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $18 price target ...

AI spending is ramping up, with Nvidia (NVDA) seeing strong Blackwell demand and IT budgets shifting toward AI investments ...

Investing.com -- Tesla's stock has faced continued pressure in 2025, but Wedbush analysts remain bullish, maintaining their ...

LOS ANGELES, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Wedbush, a Los Angeles-based financial services firm with global reach, and a legacy of innovation and client-focused investment solutions, introduces ...